Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Stock Short Interest Declines 59.8%

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) saw a large drop in short interest in September. As of September 15th, there was short interest totaling 48,204 shares, a drop of 59.8% from the August 31st total of 119,854 shares. Based on an average daily trading volume, of 259,918 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.3% of the shares of the company are short sold.

Enlivex Therapeutics Price Performance

Shares of ENLV traded down $0.03 during trading hours on Tuesday, hitting $0.48. The stock had a trading volume of 580,658 shares, compared to its average volume of 136,636. Enlivex Therapeutics has a 12 month low of $0.47 and a 12 month high of $27.15. The firm has a market capitalization of $8.40 million, a PE ratio of -0.06 and a beta of 1.42. The stock has a fifty day moving average price of $1.69 and a 200 day moving average price of $8.05.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on ENLV shares. Zacks Research upgraded shares of Enlivex Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 21st. Wall Street Zen upgraded shares of Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 29th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Enlivex Therapeutics in a report on Tuesday, September 22nd. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $247.50.

Institutional Investors Weigh In On Enlivex Therapeutics

Large investors have recently made changes to their positions in the company. Susquehanna International Group LLP grew its position in Enlivex Therapeutics by 1,428.5% during the second quarter. Susquehanna International Group LLP now owns 157,648 shares of the company’s stock valued at $87,000 after buying an additional 147,334 shares during the period. WINTON GROUP Ltd bought a new position in Enlivex Therapeutics in the second quarter worth approximately $55,000. Finally, Bank of America Corp DE raised its position in Enlivex Therapeutics by 53.2% in the first quarter. Bank of America Corp DE now owns 130,401 shares of the company’s stock worth $121,000 after acquiring an additional 45,303 shares during the period. 1.02% of the stock is currently owned by institutional investors.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd. is an Israel-based clinical-stage biotechnology company developing cell-based immunotherapies designed to restore immune-system balance, or immune homeostasis, in patients experiencing severe or dysregulated inflammation. The company focuses on conditions in which an excessive or impaired immune response may contribute to organ damage and other serious complications.

Its lead product candidate, Allocetra-OTS, is an off-the-shelf cell therapy made from healthy apoptotic cells.